Results 201 to 210 of about 6,039,132 (349)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
X. Montalban +26 more
semanticscholar +1 more source
A Prion‐Like Domain in EBV EBNA1 Promotes Phase Separation and Enables SRRM1 Splicing
This study discoveries that EBV EBNA1 behaves as a prion‐like protein, verified using cell‐based assays and the Saccharomyces cerevisiae Sup35p prion identification system. The prion‐like domain of EBNA1 drives liquid–liquid phase separation. EBNA1 interacts with the splicing factor SRSF1 to regulate the expression of the SRRM1 splicing isoforms ...
Xiaoyue Zhang +17 more
wiley +1 more source
Lifestyle factors associated with benign multiple sclerosis. [PDF]
Guo J +4 more
europepmc +1 more source
Vitamin B12 levels in the serum and cerebrospinal fluid in multiple sclerosis [PDF]
Christina Simpson
openalex +1 more source
Brain diseases involve multilayered metabolic disruptions that reshape cellular interactions and microenvironments. This review outlines core metabolic features across disease states and presents emerging nanodelivery strategies as precision tools to reprogram pathological metabolism.
Jingyi Zhou, Chen Jiang
wiley +1 more source
Comparison of immunological specificity of gamma globulin in the cerebrospinal fluid in normal and multiple sclerosis subjects [PDF]
E.A. Caspary
openalex +1 more source
Regulation of Neuroinflammation by Microglial DUBA‐IRAK1‐IKKβ Signaling Loop
The protein levels of deubiquitinating enzyme A (DUBA) are rapidly upregulated in microglia after activation of Toll‐like receptor 4 (TLR4). In turn, DUBA potentiates TLR4‐induced proinflammatory signal transduction in microglia by stabilizing interleukin‐1 receptor activated kinase 1 (IRAK1) through K48 deubiquitination.
Zhenhu Zhu +22 more
wiley +1 more source
Predictors of risk of secondary progression in multiple sclerosis. [PDF]
Laaksonen S +9 more
europepmc +1 more source
Rickettsial and Viral Antibodies in Multiple Sclerosis [PDF]
Constance A. C. Ross
openalex +1 more source

